The successful demonstration that insulin-producing β-cells can be isolated (in the form of cell clusters called islets containing β and other endocrine and nonendocrine cells) from a recently deceased donor's pancreas, then transplanted into subjects with type 1 diabetes, and thereby restore, at least temporarily, insulin-independent normoglycemia has firmly established the important “proof of concept.” Even so, worldwide efforts to advance the therapy for widespread applicability have served to focus attention on the hurdles yet to clear. This review will briefly describe the present state of the art and succinctly define the research problems being attacked along with some recent advances that demonstrate significant progress.

Since Paul Lacy's early rodent experiments in the 1960s established that pancreatic islets could be isolated from one animal and transplanted into a diabetic recipient to restore normoglycemia (1), investigators have pursued efforts to develop the therapy for clinical use. After years of development in various animal models and efforts to improve human islet isolation techniques (see [2,4] for reviews with a historical perspective), the first patient achieving short-term insulin independence was reported by the group at Washington University in St. Louis. That advance was based on new islet isolation technology utilizing islets pooled from several donors, intensive insulin treatment in the peritransplant period, and induction immunosuppression with antithymocyte globulin (ATG) to avoid glucocorticoid therapy (5). The development of new immunosuppressive drugs that allowed patients to remain off glucocorticoid therapy while awaiting subsequent islet infusions (because most recipients require islets from two or more donors) enabled the group in Edmonton to optimize the clinical islet transplantation procedure (6). The approach allowed the group to conclude that about 12,000 islet equivalents per recipient body weight (in kilograms) was required to restore insulin-independent normoglycemia (6) and sparked intense international interest and effort.

Current estimates are that ∼400 individuals have received allogeneic isolated islets since 1999 (7), with ∼40 centers actively engaged in further developing the therapy. The Edmonton case series remains the world's largest, and its data demonstrate that approximately two-thirds of the recipients enjoy insulin independence 1 year after receiving their final islet infusion (again, most recipients require islets from two or more donors). Unfortunately, islet function decreases over time such that by 5 years posttransplant, less than 10% remain insulin independent (8). On the other hand, the majority continues to display islet allograft function and, with it, decreased insulin requirements, less frequent hypoglycemia, and overall improved blood glucose control.

While other groups have reported incremental advances (i.e., predictable insulin independence using islets from a single donor, although typically from an ideal donor into a small recipient) (9), the Immune Tolerance Network multicenter trial results were as follows: less than half achieved insulin independence at 1 year and <15% remained insulin independent at 2 years (10). Further, recipients required (on average) islets from 2.1 donors, less than half of the pancreases donated for islet isolation yielded a product suitable for transplant, and for those recipients classified as insulin independent, blood glucose control was not normal for many using the American Diabetes Association criteria (10). Aside from the imperfect success, islet recipients experienced a small number of procedure-related complications (e.g., intraperitoneal bleeding, portal vein thrombosis, and gallbladder puncture).

Islets, though only small cell clusters, obey the same immunological laws that govern solid organ transplantation, i.e., allogeneic islets trigger immune-mediated rejection that must be controlled with immunosuppressive drugs, which are associated with an increased risk for declining kidney function, hyperlipidemia, infectious complications, and risk for malignancies. Also, if immunosuppression is stopped, recipients become immunologically sensitized against islet donor tissue antigens, and because islets from multiple donors are typically required, finding a suitable donor for subsequently required transplant therapy may prove difficult (e.g., should the patient develop kidney failure) (11,12). Although islets sharing HLA antigens with a recipient's previous kidney allotransplant may weaken the anti-islet donor immune response (13), repeatedly administering islet-associated alloantigens to recipients of previous allogeneic islets can jeopardize β-cell survival (14). Clearly, experience has identified problems to overcome (15), including the need to develop better assays for monitoring both anti-islet autoimmune and alloimmune responses (Table 1).

TABLE 1

Immune correlates of type 1 diabetes and islet allograft function

Immune markerCorrelateCommentReferences
Autoimmunity    
    Islet autoantibodies Baseline prediction 
  • Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative type 1 diabetic recipients of intrahepatic islet allografts.

 
(27), (28), (92
  • Insulin independence was not achieved in patients with baseline autoantibody elevations and was significantly less frequent in patients who seroconverted.

 
(92), (95
  • Patients with thyroid peroxisase autoantibodies before islet transplantation develop Graves disease after tapering of immune suppression.

 
(97
 Seroconversion 
  • Autoantibody levels had no significant association with outcome.

 
(23
  • Insulin independence was not achieved in patients with autoantibody elevations and was significantly less frequent in patients who seroconverted.

 
(92), (95
    T-cell autoreactivity Baseline prediction 
  • Patients without preexisting T-cell autoreactivity became insulin independent compared with none of the patients reactive to both GAD and IA-2 before transplantation.

  • Cellular islet-specific autoimmunity associates with clinical outcome of islet cell transplantation under ATG-tacrolimus-MMF immunosuppression.

 
(23), (98
Disease recurrence 
  • Tight correlation between human β-cell allograft recipient's metabolic outcome and assays of peripheral blood cellular auto- and alloreactivity suggests a causal relationship.

 
(22
  • Subsequent islet implantations can reduce alloreactivity for repeated HLA mismatches.

 
(13), (14
 Homeostatic expansion 
  • T-cell depletion therapy results in expansion of memory (islet autoreactive) T-cells.

 
(25
    Cytokines γ-Interferon 
  • γ-Interferon production in ELISPOT associates with type 1 diabetes.

 
(94
IL-10 
  • IL-10 production distinguishes control subjects from subjects with type 1 diabetes and associates with delayed onset of type 1 diabetes.

 
(23
Alloreactivity    
    Alloantibodies Baseline prediction 
  • Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation.

 
(11
Seroconversion 
  • Monitoring panel reactive antibodies in immunosuppressed subjects has little clinical value in islet transplant recipients. The implications of allosensitization after discontinuation of immunosuppression need to be evaluated to define the clinical impact in this patient population.

 
(12), (95
Seroconversion after immunosuppression discontinued 
  • Incidence of antidonor HLA alloantibodies posttransplant rises abruptly in subjects weaned completely from immunosuppression and is a cause for potential concern.

 
(11
    T-cell alloreactivity CTLp 
  • Informative correlate depending on immunotherapy.

 
(22), (93
  • Secondary to recurrent autoreactivity?

 
 
  • Regulatory alloreactivity associated with outcome.

 
(23
    Cytokines γ-Interferon 
  • Positive association with mixed lymphocyte reaction (MLR) assay.

 
(23
IL-10 
  • Marker of protection/preservation/tolerance.

 
(23), (96
Cytotoxic T-cell genes    
    Granzyme B Loss of function 
  • Granzyme B was the most reliable indicator of ongoing graft loss. The results suggest that, when taken into consideration with other clinical parameters, CTL gene expression may predict islet allograft loss.

 
(20), (95
    Perforin and Fas-L Increased insulin needs 
  • The decreased expression of perforin and Fas-L in patients with long-term type 1 diabetes might contribute to the inability to maintain normal levels of peripheral tolerance, which is essential for protection from autoimmune disease.

 
(20), (95
Immune markerCorrelateCommentReferences
Autoimmunity    
    Islet autoantibodies Baseline prediction 
  • Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative type 1 diabetic recipients of intrahepatic islet allografts.

 
(27), (28), (92
  • Insulin independence was not achieved in patients with baseline autoantibody elevations and was significantly less frequent in patients who seroconverted.

 
(92), (95
  • Patients with thyroid peroxisase autoantibodies before islet transplantation develop Graves disease after tapering of immune suppression.

 
(97
 Seroconversion 
  • Autoantibody levels had no significant association with outcome.

 
(23
  • Insulin independence was not achieved in patients with autoantibody elevations and was significantly less frequent in patients who seroconverted.

 
(92), (95
    T-cell autoreactivity Baseline prediction 
  • Patients without preexisting T-cell autoreactivity became insulin independent compared with none of the patients reactive to both GAD and IA-2 before transplantation.

  • Cellular islet-specific autoimmunity associates with clinical outcome of islet cell transplantation under ATG-tacrolimus-MMF immunosuppression.

 
(23), (98
Disease recurrence 
  • Tight correlation between human β-cell allograft recipient's metabolic outcome and assays of peripheral blood cellular auto- and alloreactivity suggests a causal relationship.

 
(22
  • Subsequent islet implantations can reduce alloreactivity for repeated HLA mismatches.

 
(13), (14
 Homeostatic expansion 
  • T-cell depletion therapy results in expansion of memory (islet autoreactive) T-cells.

 
(25
    Cytokines γ-Interferon 
  • γ-Interferon production in ELISPOT associates with type 1 diabetes.

 
(94
IL-10 
  • IL-10 production distinguishes control subjects from subjects with type 1 diabetes and associates with delayed onset of type 1 diabetes.

 
(23
Alloreactivity    
    Alloantibodies Baseline prediction 
  • Pretransplant HLA antibodies are associated with reduced graft survival after clinical islet transplantation.

 
(11
Seroconversion 
  • Monitoring panel reactive antibodies in immunosuppressed subjects has little clinical value in islet transplant recipients. The implications of allosensitization after discontinuation of immunosuppression need to be evaluated to define the clinical impact in this patient population.

 
(12), (95
Seroconversion after immunosuppression discontinued 
  • Incidence of antidonor HLA alloantibodies posttransplant rises abruptly in subjects weaned completely from immunosuppression and is a cause for potential concern.

 
(11
    T-cell alloreactivity CTLp 
  • Informative correlate depending on immunotherapy.

 
(22), (93
  • Secondary to recurrent autoreactivity?

 
 
  • Regulatory alloreactivity associated with outcome.

 
(23
    Cytokines γ-Interferon 
  • Positive association with mixed lymphocyte reaction (MLR) assay.

 
(23
IL-10 
  • Marker of protection/preservation/tolerance.

 
(23), (96
Cytotoxic T-cell genes    
    Granzyme B Loss of function 
  • Granzyme B was the most reliable indicator of ongoing graft loss. The results suggest that, when taken into consideration with other clinical parameters, CTL gene expression may predict islet allograft loss.

 
(20), (95
    Perforin and Fas-L Increased insulin needs 
  • The decreased expression of perforin and Fas-L in patients with long-term type 1 diabetes might contribute to the inability to maintain normal levels of peripheral tolerance, which is essential for protection from autoimmune disease.

 
(20), (95

Assays for immunological monitoring.

T-cell assays now can, with reasonable accuracy, identify anti–β-cell immune responses in individuals with type 1 diabetes compared with nondiabetic control subjects (16). The best validated assays measure T-cell proliferation in response to diabetes-related antigens. One such assay uses predefined diabetes-related peptide or protein antigens and includes exogenous interleukin (IL)-2 in the assay medium (17), whereas another group uses antigens eluted from gel-fractionated human islet cell proteins (18,19). Neither assay has been validated for its ability to monitor anti–β-cell immunoreactivity following an islet transplant, however.

Monitoring cellular-mediated immune reactivity using parameters like granzyme B, perforin, and Fas ligand can predict deteriorating islet allograft function. Indeed, studies correlating islet allograft recipients' C-peptide production with cytotoxic lymphocyte mRNA levels determined with real-time PCR have shown that the cytotoxic lymphocyte gene mRNA levels are increased 25–203 days before hyperglycemia and loss of insulin independence (20,21), with granzyme B most reliably indicating ongoing graft loss. Unfortunately, such transcriptional immune correlates do not specify whether the type of immune reaction against the islet allograft represents recurrent autoimmunity and/or alloimmunity. Experience from solid organ transplantation (kidney, liver, and heart) has taught that patient management is critically dependent on rapid and validated assays to monitor graft function and antigraft immune responses; yet at present, no such assays have been validated to monitor islet rejection.

Monitoring anti–β-cell autoimmunity.

Assays monitoring anti–β-cell autoimmunity after islet transplantation correlate with progressively deteriorating β-cell function, whereas the absence of both allo- and autoreactivity has been associated with successful islet allograft outcome (22). Further, assays that measure anti-islet cellular autoimmunity (performed before a patient receives an islet transplant) are associated with delayed insulin independence, less C-peptide production during the first year after transplantation, and more rapid return to insulin dependence (23). Notably, in this study islet allograft outcome did not appear to be influenced by either anti–β-cell autoantibody levels before or after islet implantation or assays measuring cellular alloreactivity. Recent HLA-A2insulin tetramer staining assays that focus on CD8+ (cytotoxic) T-cells (at least for the ∼50% of Caucasians carrying the HLA-A2 allele) have proved useful to detect insulin-specific T-cells correlating with recurrent autoimmunity and subsequent graft failure in islet transplant recipients (24). The importance of assays capable of monitoring the anti–β-cell immune response has recently been highlighted; the IL-2 receptor–blocking antibody strategy commonly used for induction immunotherapy before the islet allograft infusion has been associated with increased IL-7 and IL-15 serum concentrations and with the homeostatic proliferation of memory T-cells reactive against islet autoantigens, e.g., autoreactive GAD65-specific T-cell clones (25). Although recent studies enrolling kidney allograft recipients have found that anti–IL-2 receptor–based induction regimens are not as effective as ATG-based depletion strategies to prevent allograft rejection (26), it is not known whether such a depletion-based strategy would better protect allogeneic islets transplanted into a host with anti–β-cell autoimmunity. Clearly, such studies should be done.

Autoantibody titers and their relevance to graft function.

Although autoantibodies have proven most useful for predicting onset of type 1 diabetes, their predictive power in the islet transplantation setting is controversial. A correlation between increasing GAD65 and insulinoma-associated protein 2 (IA-2) autoantibody titers and graft loss as a result of recurrent autoimmunity has been reported in pancreas transplantation (27,28). With regard to islet transplantation, some have reported earlier islet graft failure in autoantibody-positive compared with autoantibody-negative recipients (29,30), whereas other investigators have found no such association (23,31). This may in part be attributed to different immune suppressive regimes and graft composition and transplantation procedures.

Alloimmune responses.

Most islet allograft recipients develop antidonor antibodies (11,12), typically after immunosuppressive medications are tapered due to either reduced islet allograft function or intolerable immunosuppressant agent toxicity, but islet allograft failure has also been correlated with increased alloantibody titers (32). Presence of specific antidonor alloantibodies should exclude patients from receiving islets from donors expressing the recognized HLA allodeterminants (i.e., those with a positive crossmatch) because they predict graft failure (11,23). Assays detecting recipient antidonor T-cell reactivity also correlate with graft failure in recipients of islet-alone allografts (22,23). Cytokine profiles also correlate with islet allograft fate (23) in that those skewed toward a regulatory phenotype were found in insulin-independent recipients, but not in insulin-requiring recipients. In particular, circulating IL-10 (a cytokine associated with regulatory T-cells) inversely correlated with proliferation in allo-mixed lymphocyte cultures and with alloreactive cytotoxic T-cell precursor frequency. These results imply that immune monitoring may provide surrogate markers to guide immunosuppressive agent dosing in the future.

Innate immune system effects on islet allograft survival.

As much as 50–60% of the transplanted islets may be lost in the early posttransplant period (33), thereby contributing to the need to transplant islets from multiple donors to achieve insulin independence. Islets express tissue factor (TF)—a 47 kDa transmembrane glycoprotein that initiates the extrinsic coagulation system and is pivotal for activation of the intrinsic pathway. Vascular injury exposes TF to soluble coagulation proteins and triggers clotting (34). In addition, TF binds to factor VIIa and thereby activates a number of intracellular signals that culminate in cell proliferation, diapedesis, and inflammation (35). The intravascular infusion of isolated islets results in TF-stimulated nonspecific inflammatory and coagulation pathways (36,,,40) promoting a so-called instant blood-mediated inflammatory reaction (IBMIR) that is detrimental to islet survival (41,,44) and may delay islet revascularization and engraftment (45). IBMIR has been reported in pigs after intraportal islet transplantation (46) and in human islet allotransplantation (36,46,47). Administering a humanized anti–TF-specific monoclonal antibody (CNTO 859) (48) to nonhuman primate islet allograft recipients given a marginal islet mass significantly enhanced engraftment and function (49). The recent demonstration that potent inhibitors of inflammation, including α1-antitrypsin (50) and imatinib (a tyrosine kinase inhibitor) (51), can restore euglycemia in NOD mice with incipient diabetes further supports the critical importance of limiting innate inflammatory events in the early posttransplant period. The original Edmonton protocol has been modified in several ways; e.g., most centers now culture isolated islets to decrease tissue factor expression and administer anti-inflammatory tumor necrosis factor-α monoclonal antibody therapy peritransplant, recipients are now typically treated with heparin postislet infusion, and most teams now try to minimize sirolimus exposure. These and other changes may improve outcomes like those recently reported from the University of Minnesota (52), but objectively identifying which factor or group of factors that may have resulted in the improved outcome is still difficult due to the small number of subjects who are reported in such studies.

Safely targeting the anti–β-cell immune and inflammatory responses with either drug- or regulatory cell–based strategies has proved a major challenge. In addition to the toxicity associated with usual immune suppression discussed above, several agents appear to interfere with immune tolerance, and all drugs currently used clinically to prevent islet allograft loss adversely affect β-cell function and glycemia control (4). Specific issues with current regimens are as follows: sirolimus impairs engraftment (53), interferes with angiogenesis (54), induces insulin resistance (55), and inhibits β-cell replication (56), while it, as well as corticosteroids, tacrolimus (57), and mycofenolate mofetil (MMF), decreases insulin transcription and translation (rev. in 4). Lastly, a recent study suggests that MMF also inhibits β-cell neogenesis (58). The need for different strategies to prevent allograft rejection and/or recurrent islet autoimmunity is currently debated. In the most widely studied rodent models of type 1 diabetes (i.e., the NOD mouse and BB rat), immunosuppression that readily controls allograft rejection is unable to protect against recurrent autoimmunity. In contrast, after clinical pancreas transplantation both allo- and autoimmune responses are controlled by standard immunosuppression. The notion that autoimmunity in human type 1 diabetes can be controlled by a standard immunosuppression (e.g., low-dose cyclosporine A) is supported by clinical studies (59). Many novel immunotherapies are under development, yet most are directed at controlling alloimmune responses (60), whereas the anti–β-cell autoimmunity predating any therapeutic transplant efforts in subjects with type 1 diabetes may well pose particular impediments. For example, immunotherapies that prevent autoimmune diabetes in preclinical models have been less effective when tested in humans shortly following disease onset (61,63).

An additional consideration for enhancing outcomes in islet transplantation is identification of alternative implantation sites (Fig. 1). Infusing islets into the liver via the portal vein has been the site of choice for clinical islet transplantation and is the only site that has routinely demonstrated success in large animal models. The reasoning has been that the pancreas normally secretes insulin into the portal vein, intrahepatic islets avoid the systemic hyperinsulinemia observed in some pancreas allograft recipients, the portal blood is oxygenated (albeit at lower than arterial tensions) such that the isolated islets are exposed to oxygen until they can revascularize, and the portal vein can be accessed using a minimally invasive procedure. Disadvantages of the portal vein include the aforementioned IBMIR, higher levels of immune suppression in the portal circulation that may impair islet engraftment, vascularity, or function (4;53,,,,58;60), periportal steatosis (64,65), and an inability to routinely biopsy the transplanted islets because they are dispersed within the liver. Isolated islets have been infused via the celiac artery into nonhuman primates, reasoning that the arterial tree could be more safely accessed and that intra-arterial islets might be more readily revascularized, but islet function was promptly lost (66). The highly vascular omental pouch of diabetic dogs has been successfully used as a site for autologous islet implants (67,69), and N.S.K. and colleagues (70) have demonstrated the feasibility of this site for allogeneic islet implant in cynomolgus monkeys. Experimental efforts testing the pancreas as an implantation site have also been reported in animal models (71). Recently, implanting a child's autologous islets into an intramuscular site has been reported to decrease her insulin requirements and help maintain euglycemia (72). Identification of scaffolds, gels, matrices, and devices that can enable exploitation of alternative sites is an active area of investigation.

FIG. 1.

Potential alternative islet implantation sites. Efforts directed to promote improved islet graft function and survival have led to studies testing alternative implantation sites, mostly in preclinical animal models, although the intramuscular route has shown some promise in the clinic (72). Recent pig model studies (73) have suggested promise for endoscopic transplant of the islets into the gastric submucosal space.

FIG. 1.

Potential alternative islet implantation sites. Efforts directed to promote improved islet graft function and survival have led to studies testing alternative implantation sites, mostly in preclinical animal models, although the intramuscular route has shown some promise in the clinic (72). Recent pig model studies (73) have suggested promise for endoscopic transplant of the islets into the gastric submucosal space.

Close modal

Cells capable of physiologically regulated insulin secretion.

Assuming techniques can be developed to safely protect insulin-producing cells once they are implanted into the diabetic individual, a widely applicable strategy will require a renewable β-like cell source. In the U.S. alone, over 22 million people have diabetes (type 1 diabetes or type 2 diabetes), and yet the country produces only about 8,000 organ donors each year. Because at present only approximately half of the isolation efforts yield islets suitable for transplant (10) and because recipients usually require islets from multiple donors (10), only ∼2,000 subjects in the U.S. could benefit from an islet transplant each year. Efforts to expand the pancreas donor pool (e.g., including non–heart-beating donors [74]) improve isolation techniques to more likely yield transplantable islets from each pancreas, and strategies to decrease a recipient's islet requirements, even when combined, will only marginally improve the current disparity between islet supply and potential recipients. Further, while recent promising efforts report the transplant of islets isolated from a living donor (75), other studies reporting long-term metabolic consequences for those donating half their pancreas considerably temper any optimism that living islet donors can fill the insulin-producing cell void (76).

Several groups are therefore pursuing strategies (Fig. 2) designed to use renewable sources for the insulin-producing cells; e.g., xenogeneic islets (predominantly from pigs), cells induced to differentiate from embryonic stem (ES) cells (or the related inducible pluripotent stem cells), or cells “reprogrammed” from their initial phenotype into β-like cells.

FIG. 2.

Recognizing the tremendous disparity between the islet number that can be isolated from cadaveric donors and the potential recipient population, many investigators are working to develop a renewable and cost-efficient source of islets or islet-like clusters. Each strategy has potential advantages but also unique problems to overcome.

FIG. 2.

Recognizing the tremendous disparity between the islet number that can be isolated from cadaveric donors and the potential recipient population, many investigators are working to develop a renewable and cost-efficient source of islets or islet-like clusters. Each strategy has potential advantages but also unique problems to overcome.

Close modal

Pig islets offer many advantages as a renewable islet source. Pigs have large litters, and the animals mature quickly; glucose set points for insulin release are similar in pigs and humans; pig insulin was used clinically for decades insuring its safety; and the widespread use of pigs for agricultural reasons minimizes animal rights concerns that may exist for other potential xenogeneic sources (15). Further, some investigators have transplanted isolated pig islets to diabetic nonhuman primates and thereby restored temporary near-normal glycemia to the immunosuppressed recipients (77,78). Factors limiting this xenogeneic islet source include particular species-specific difficulties associated with islet isolation and to-date only theoretical zoonotic infectious concerns; i.e., the species is known to harbor certain pig endogenous retroviruses (PERVs), and some have suggested that a large pig tissue inoculum, especially if placed in an immunosuppressed host, may support adaptation of the pig virus for human cells. More importantly, pig tissues express a cell surface moiety (galactose α1,3 galactose) against which humans have high-titer antibodies leading to accelerated and reinforced rejection. The latter problem is being attacked through the creation of genetically altered pigs (79,80).

Considerable excitement surrounds reports that human ES cells can be cultured in vitro under conditions that support differentiation into definitive pancreatic endoderm and even β-like cells, except that such in vitro–produced cells fail to secrete insulin in a glucose-regulated fashion (81). However, when definitive pancreatic endoderm is implanted into immunoincompetent mice, many of the cells differentiate into β-like cells that release insulin in response to glucose (82). Unfortunately, some of the implanted cells also display teratogenic potential, and it is not yet possible to select the desired cells from the undesired ones. Clearly, regulatory agencies such as the U.S. Food and Drug Administration would and should insist on strategies to overcome this shortfall. Lastly, unless ES cell lines can be established for all potential HLA haplotypes, the β-like cells produced from a particular ES line would face immune destruction from both antiallogeneic (unless the ES haplotype completely matched the recipient) and autoimmune processes. Recent progress with somatic cell nuclear transfer in the nonhuman primate (83) provides one potential solution for creating ES cells for any individual from a mature cell's nucleus taken from that individual, assuming moral/ethical issues can be worked out.

Another potential solution to overcome the alloimmune response has been offered by recent successes to create ES-like cells from fully differentiated somatic cells, so-called induced pluripotent stem (IPS) cells. This advance raises the possibility that each individual could serve as his or her own stem cell source to create new β-like cells. Unfortunately, at present the process of dedifferentiating such somatic cells requires transfection with potentially cell-transforming transcription factors like c-myc, and most strategies utilize viral vectors that integrate into the genome and thus further increase concerns that such cells may display malignant potential. Recent reports have shown that nonintegrating viral vectors can promote IPS cell generation, whereas others are conducting studies to avoid transcription factors altogether (84,85). By utilizing each individual's own cells to create new β-like cells, one anti–β-cell immune response (alloimmunity) is eliminated while another is quite possibly exacerbated (autoimmunity); i.e., multiple anti–β-cell T-cell clones exist in the individual with type 1 diabetes, and each T-cell recognizes major histocompatibility complex (MHC)-restricted β-cell antigenic peptides. For any given individual with type 1 diabetes, all such autoreactive T-cells would be able to recognize β-cells created from that same individual's IPS cells because the β-cells would express all the appropriate MHC restriction elements. Indeed, recurrent anti–β-cell–specific CD8 T-cell–mediated reactivity associated with loss of islet allograft function has been shown in cases where the donor shares HLA class 1 alleles with the recipient (86).

Lastly, transfecting rodent pancreatic acinar cells with an adenoviral vector mixture driving temporary expression of the transcription factors (Pdx-1, Ngn-3, and Maf A) appears to convert those mature pancreatic cells into β-like cells without an intermediate dedifferentiated state, so-called lineage reprogramming (87). Ongoing studies are exploring whether more readily accessible cells (e.g., cultured hepatocytes) might be similarly reprogrammed with these (or other) transcription factors. The facts that only transient vector-driven transcription factor expression is required to reprogram the cells and that the strategy avoids the dedifferentiated cell state may decrease the transformation potential, but recurrent autoimmune destruction would remain a problem.

Progress developing renewable cellular sources capable of physiologically regulated insulin secretion, assays for monitoring the immune response against those cells, and therapies to preserve those cells' function once transplanted have all converged to bring into clearer focus the long–dreamed of “finish line” (i.e., curing diabetes by correcting the afflicted individual's insulin deficiency). That said, prudence dictates that investigators begin planning for the end-game strategy to start clinically testing cell transplant–based strategies. The process will not be fast or trivial, and yet we argue that “fast-track” approaches should be considered with great caution, especially with regard to stem cell–based approaches. For instance, most would agree that the University of Pennsylvania's unfortunate gene therapy experience not only contributed to that study's first enrollee's premature death but that the entire gene therapy field was set back (88). We offer the following thoughts for forward progress.

In most developed countries, pancreas transplantation is the only accepted procedure to achieve normoglycemia. For pancreas transplantation, established techniques exist to procure the donated organ (or part of it) from both living and diseased donors and long-term graft function is similar to other whole-organ allografts. However, the pancreas transplant procedure is limited by additional risks related to the organ's exocrine enzyme production. While therapy using isolated human islets may be on the brink of becoming an accepted clinical therapy for a small type 1 diabetic subgroup with most severe hypoglycemia unawareness and while isolated islets enjoy an advantage over the intact pancreas in that the exocrine component is removed during the islet isolation process, those same isolation procedures impose ischemic and mechanical damages and thereby induce undesired cellular stress responses. Moreover, the injection of the cells into the blood stream is unique, and it is now generally accepted that only 10–20% of the islets transplanted survive the procedure and contribute to the recipient's metabolic control. And although some mechanisms underlying the substantial islet loss have been discussed, much remains unknown. Data obtained from rodent models suggest that these limitations can be overcome. Whether they can be successfully translated to larger animals and to humans is the focus of several ongoing studies.

Taking into consideration the enormous recent improvements in the type 1 diabetes treatment, the ultimate indications for islet transplantation could only be justified if there were almost no side effects related to the procedure and the immunosuppression/tolerance protocols applied. One could argue that there will be no need for xenogeneic or stem cell–derived β-like cells until robust immune tolerance or protection can be induced without severe side effects. The many forces conspiring to impair islet (or islet-like cell clusters) function or survival (Fig. 3) are all rich sources for study because most, if not all, will need be overcome.

FIG. 3.

Factors limiting islet graft function and survival. Present understanding is that transplanted islets (or islet-like clusters) face myriad overlapping forces all conspiring to limit graft function and/or survival. Effective strategies to develop islet transplantation for widespread clinical application will likely require effective countermeasures for each identified problem.

FIG. 3.

Factors limiting islet graft function and survival. Present understanding is that transplanted islets (or islet-like clusters) face myriad overlapping forces all conspiring to limit graft function and/or survival. Effective strategies to develop islet transplantation for widespread clinical application will likely require effective countermeasures for each identified problem.

Close modal

Testing therapies designed to restore anti–β-cell immune tolerance.

For therapies designed to generally weaken the anti–β-cell immune response or augment immunoregulatory processes, we point out that most therapies working in one T-cell–mediated disease process also generally work when applied to a different T-cell–mediated illness. Given that the prognosis for individuals with recent-onset type 1 diabetes is now outstanding (excess mortality of ∼0.1% per year [89]), the potential immunotherapy should have a safety profile known to not exceed that rate. For instance, the anti-VLA4 antibody (natalizumab) is estimated to carry with it 1 in 1,000 risk for progressive multifocal leukencephalopathy such that its use in subjects with recent-onset type 1 diabetes might be unwise. Even individuals with long-standing type 1 diabetes sufficiently severe to be listed for a solitary pancreas transplant have an annual mortality of 1–2% (90). Further, using islet transplantation as a model to test new immunomodulatory approaches is complicated by our present inability to reliably predict islet allograft rejection from either allo- or autoimmune processes and by our inability to reverse an early rejection episode. The current need for islets from two or more donors and the resulting allosensitization raise additional concerns. Lastly, many immunotherapeutic agents appear to directly influence β-cell function, vascularity, survival, and/or proliferative capacity (4;53,,,,58;91). Consequently, one might argue that efforts directed to test therapies designed to promote immune tolerance should await the ability to promote long-term insulin independence to recipients receiving islets isolated from a single donor. In the meantime, novel immunomodulatory therapies could, in general, be first tested in another setting such as kidney transplantation where disease prognosis is worse, techniques for following the antigraft immune response exist, one donor's tissue suffices to restore the recipient's lost organ function, the immunological barrier can be determined (from the HLA mismatch score and by avoiding autoimmunity), and effective rescue therapies exist should the experimental immunotherapy fail. On the other hand, a transplanted kidney is a life-saving procedure, and some have questioned the ethics of testing new immunotherapies when effective ones exist. Further, acute rejection episodes are considered a surgical emergency and a potential threat for both the patient and the graft. Also, any immunomodulatory therapy will eventually need to be evaluated in individuals with autoimmune type 1 diabetes. These imponderable variables lead most to conclude that individual investigators should pursue specific protocol plans as guided by external peer review, their local institutional review board, and proper informed consent from the potential protocol participant.

Testing the cellular source for physiologically regulated insulin secretion.

In view of the potential adverse effects associated with xenogeneic cells (zoonotic infection) or cells engineered in vitro, most investigators agree that testing of the insulin-producing cells in a chronic large animal (ideally nonhuman primate) model should be performed if possible. One disadvantage of the nonhuman primate model is that anti–β-cell autoimmunity has not been reported in the species.

Lastly, as discussed throughout this review, because investigators are attempting to safely manipulate the immune system to prevent it from killing transplanted insulin-producing cells, it only makes sense for scientists to develop techniques to better measure the immune processes that affect the transplanted insulin-producing cells and to be able to quantify the insulin-producing cell mass in vivo. If successfully achieved, these techniques will become of immense importance not only for the development of replacement therapies for type 1 diabetes but also for early interventions (e.g., immune intervention for those at risk to prevent the disease or drugs to stimulate β-cell function and proliferation in those recently diagnosed) aiming to prevent clinical overt diabetes (type 1 or type 2).

D.M.H. is supported by the Intramural Research Program of the National Institute of Diabetes and Digestive and Kidney Diseases/National Institutes of Health of the Department of Health and Human Services.

No potential conflicts of interest relevant to this article were reported.

1
Ballinger
WF
,
Lacy
PE
:
Transplantation of intact pancreatic islets in rats
.
Surgery
1972
;
72
:
175
186
2
Pileggi
A
,
Ricordi
C
,
Kenyon
NS
,
Froud
T
,
Baidal
DA
,
Kahn
A
,
Selvaggi
G
,
Alejandro
R
:
Twenty years of clinical islet transplantation at the Diabetes Research Institute–University of Miami
.
Clin Transpl
2004
;
177
204
3
Stock
PG
,
Bluestone
JA
:
Beta-cell replacement for type 1 diabetes
.
Annu Rev Med
2004
;
55
:
133
156
4
Robertson
RP
:
Islet transplantation as a treatment for diabetes—a work in progress
.
N Engl J Med
2004
;
350
:
694
705
5
Scharp
DW
,
Lacy
PE
,
Santiago
JV
,
McCullough
CS
,
Weide
LG
,
Falqui
L
,
Marchetti
P
,
Gingerich
RL
,
Jaffe
AS
,
Cryer
PE
:
Insulin independence after islet transplantation into type 1 diabetic patient
.
Diabetes
1990
;
39
:
515
518
6
Shapiro
AM
,
Lakey
JR
,
Ryan
EA
,
Korbutt
GS
,
Toth
E
,
Warnock
GL
,
Kneteman
NM
,
Rajotte
RV
:
Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen
.
N Engl J Med
2000
;
343
:
230
238
7
Alejandro
R
,
Barton
FB
,
Hering
BJ
,
Wease
S
:
2008 Update from the Collaborative Islet Transplant Registry
.
Transplantation
2008
;
86
:
1783
1788
8
Ryan
EA
,
Paty
BW
,
Senior
PA
,
Bigam
D
,
Alfadhli
E
,
Kneteman
NM
,
Lakey
JR
,
Shapiro
AM
:
Five-year follow-up after clinical islet transplantation
.
Diabetes
2005
;
54
:
2060
2069
9
Hering
BJ
,
Kandaswamy
R
,
Ansite
JD
,
Eckman
PM
,
Nakano
M
,
Sawada
T
,
Matsumoto
I
,
Ihm
SH
,
Zhang
HJ
,
Parkey
J
,
Hunter
DW
,
Sutherland
DE
:
Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes
.
JAMA
2005
;
293
:
830
835
10
Shapiro
AM
,
Ricordi
C
,
Hering
BJ
,
Auchincloss
H
,
Lindblad
R
,
Robertson
RP
,
Secchi
A
,
Brendel
MD
,
Berney
T
,
Brennan
DC
,
Cagliero
E
,
Alejandro
R
,
Ryan
EA
,
DiMercurio
B
,
Morel
P
,
Polonsky
KS
,
Reems
JA
,
Bretzel
RG
,
Bertuzzi
F
,
Froud
T
,
Kandaswamy
R
,
Sutherland
DE
,
Eisenbarth
G
,
Segal
M
,
Preiksaitis
J
,
Korbutt
GS
,
Barton
FB
,
Viviano
L
,
Seyfert-Margolis
V
,
Bluestone
J
,
Lakey
JR
:
International trial of the Edmonton protocol for islet transplantation
.
N Engl J Med
2006
;
355
:
1318
1330
11
Campbell
PM
,
Senior
PA
,
Salam
A
,
Labranche
K
,
Bigam
DL
,
Kneteman
NM
,
Imes
S
,
Halpin
A
,
Ryan
EA
,
Shapiro
AM
:
High risk of sensitization after failed islet transplantation
.
Am J Transplant
2007
;
7
:
2311
2317
12
Cardani
R
,
Pileggi
A
,
Ricordi
C
,
Gomez
C
,
Baidal
DA
,
Ponte
GG
,
Mineo
D
,
Faradji
RN
,
Froud
T
,
Ciancio
G
,
Esquenazi
V
,
Burke
GW
 3rd
,
Selvaggi
G
,
Miller
J
,
Kenyon
NS
,
Alejandro
R
:
Allosensitization of islet allograft recipients
.
Transplantation
2007
;
84
:
1413
1427
13
Stobbe
I
,
Duinkerken
G
,
van Rood
JJ
,
Lernmark
A
,
Keymeulen
B
,
Pipeleers
D
,
De Vries
RR
,
Glass
FH
,
Roep
BO
:
Tolerance to kidney allograft transplanted into type I diabetic patients persists after in vivo challenge with pancreatic islet allografts that express repeated mismatches
.
Diabetologia
1999
;
42
:
1379
1380
14
van Kampen
CA
,
van de Linde
P
,
Duinkerken
G
,
van Schip
JJ
,
Roelen
DL
,
Keymeulen
B
,
Pipeleers
DG
,
Claas
FH
,
Roep
BO
:
Alloreactivity against repeated HLA mismatches of sequential islet grafts transplanted in non-uremic type 1 diabetes patients
.
Transplantation
2005
;
80
:
118
126
15
Rother
KI
,
Harlan
DM
:
Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus
.
J Clin Invest
2004
;
114
:
877
883
16
Seyfert-Margolis
V
,
Gisler
TD
,
Asare
AL
,
Wang
RS
,
Dosch
HM
,
Brooks-Worrell
B
,
Eisenbarth
GS
,
Palmer
JP
,
Greenbaum
CJ
,
Gitelman
SE
,
Nepom
GT
,
Bluestone
JA
,
Herold
KC
:
Analysis of T-cell assays to measure autoimmune responses in subjects with type 1 diabetes: results of a blinded controlled study
.
Diabetes
2006
;
55
:
2588
2594
17
Dosch
H
,
Cheung
RK
,
Karges
W
,
Pietropaolo
M
,
Becker
DJ
:
Persistent T cell anergy in human type 1 diabetes
.
J Immunol
1999
;
163
:
6933
6940
18
Brooks-Worrell
BM
,
Greenbaum
CJ
,
Palmer
JP
,
Pihoker
C
:
Autoimmunity to islet proteins in children diagnosed with new-onset diabetes
.
J Clin Endocrinol Metab
2004
;
89
:
2222
2227
19
Brooks-Worrell
BM
,
Starkebaum
GA
,
Greenbaum
C
,
Palmer
JP
:
Peripheral blood mononuclear cells of insulin-dependent diabetic patients respond to multiple islet cell proteins
.
J Immunol
1996
;
157
:
5668
5674
20
Han
D
,
Xu
X
,
Baidal
D
,
Leith
J
,
Ricordi
C
,
Alejandro
R
,
Kenyon
NS
:
Assessment of cytotoxic lymphocyte gene expression in the peripheral blood of human islet allograft recipients: elevation precedes clinical evidence of rejection
.
Diabetes
2004
;
53
:
2281
2290
21
Froud
T
,
Ricordi
C
,
Baidal
DA
,
Hafiz
MM
,
Ponte
G
,
Cure
P
,
Pileggi
A
,
Poggioli
R
,
Ichii
H
,
Khan
A
,
Ferreira
JV
,
Pugliese
A
,
Esquenazi
VV
,
Kenyon
NS
,
Alejandro
R
:
Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience
.
Am J Transplant
2005
;
5
:
2037
2046
22
Roep
BO
,
Stobbe
I
,
Duinkerken
G
,
van Rood
JJ
,
Lernmark
A
,
Keymeulen
B
,
Pipeleers
D
,
Claas
FH
,
De Vries
RR
:
Auto- and alloimmune reactivity to human islet allografts transplanted into type 1 diabetic patients
.
Diabetes
1999
;
48
:
484
490
23
Huurman
VA
,
Hilbrands
R
,
Pinkse
GG
,
Gillard
P
,
Duinkerken
G
,
van de Linde
P
,
van der Meer-Prins
PM
,
Versteeg-van der Voort Maarschalk
MF
,
Verbeeck
K
,
Alizadeh
BZ
,
Mathieu
C
,
Gorus
FK
,
Roelen
DL
,
Claas
FH
,
Keymeulen
B
,
Pipeleers
DG
,
Roep
BO
:
Cellular islet autoimmunity associates with clinical outcome of islet cell transplantation
.
PLoS One
2008
;
3
:
e2435
24
Pinkse
GG
,
Boitard
C
,
Tree
TI
,
Peakman
M
,
Roep
BO
:
HLA class I epitope discovery in type 1 diabetes: independent and reproducible identification of proinsulin epitopes of CD8 T cells–report of the IDS T Cell Workshop Committee
.
Ann N Y Acad Sci
2006
;
1079
:
19
23
25
Monti
P
,
Scirpoli
M
,
Maffi
P
,
Ghidoli
N
,
De Taddeo
F
,
Bertuzzi
F
,
Piemonti
L
,
Falcone
M
,
Secchi
A
,
Bonifacio
E
:
Islet transplantation in patients with autoimmune diabetes induces homeostatic cytokines that expand autoreactive memory T cells
.
J Clin Invest
2008
;
118
:
1806
1814
26
Brennan
DC
,
Daller
JA
,
Lake
KD
,
Cibrik
D
,
Del Castillo
D
:
Rabbit antithymocyte globulin versus basiliximab in renal transplantation
.
N Engl J Med
2006
;
355
:
1967
1977
27
Braghi
S
,
Bonifacio
E
,
Secchi
A
,
Di Carlo
V
,
Pozza
G
,
Bosi
E
:
Modulation of humoral islet autoimmunity by pancreas allotransplantation influences allograft outcome in patients with type 1 diabetes
.
Diabetes
2000
;
49
:
218
224
28
Bosi
E
,
Bottazzo
GF
,
Secchi
A
,
Pozza
G
,
Shattock
M
,
Saunders
A
,
Gelet
A
,
Touraine
JL
,
Traeger
J
,
Dubernard
JM
:
Islet cell autoimmunity in type I diabetic patients after HLA-mismatched pancreas transplantation
.
Diabetes
1989
;
38
(
Suppl. 1
):
82
84
29
Jaeger
C
,
Brendel
MD
,
Hering
BJ
,
Eckhard
M
,
Bretzel
RG
:
Progressive islet graft failure occurs significantly earlier in autoantibody-positive than in autoantibody-negative IDDM recipients of intrahepatic islet allografts
.
Diabetes
1997
;
46
:
1907
1910
30
Jaeger
C
,
Brendel
MD
,
Eckhard
M
,
Bretzel
RG
:
Islet autoantibodies as potential markers for disease recurrence in clinical islet transplantation
.
Exp Clin Endocrinol Diabetes
2000
;
108
:
328
333
31
Keymeulen
B
,
Ling
Z
,
Gorus
FK
,
Delvaux
G
,
Bouwens
L
,
Grupping
A
,
Hendrieckx
C
,
Pipeleers-Marichal
M
,
Van Schravendijk
C
,
Salmela
K
,
Pipeleers
DG
:
Implantation of standardized beta-cell grafts in a liver segment of IDDM patients: graft and recipients characteristics in two cases of insulin-independence under maintenance immunosuppression for prior kidney graft
.
Diabetologia
1998
;
41
:
452
459
32
Olack
BJ
,
Swanson
CJ
,
Flavin
KS
,
Phelan
D
,
Brennan
DC
,
White
NH
,
Lacy
PE
,
Scharp
DW
,
Poindexter
N
,
Mohanakumar
T
:
Sensitization to HLA antigens in islet recipients with failing transplants
.
Transplant Proc
1997
;
29
:
2268
2269
33
Biarnes
M
,
Montolio
M
,
Nacher
V
,
Raurell
M
,
Soler
J
,
Montanya
E
:
β-Cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia
.
Diabetes
2002
;
51
:
66
72
34
Dahlback
B
:
Blood coagulation
.
Lancet
2000
;
355
:
1627
1632
35
Versteeg
HH
,
Peppelenbosch
MP
,
Spek
CA
:
The pleiotropic effects of tissue factor: a possible role for factor VIIa-induced intracellular signalling?
Thromb Haemost
2001
;
86
:
1353
1359
36
Moberg
L
,
Johansson
H
,
Lukinius
A
,
Berne
C
,
Foss
A
,
Kallen
R
,
Ostraat
O
,
Salmela
K
,
Tibell
A
,
Tufveson
G
,
Elgue
G
,
Nilsson
EK
,
Korsgren
O
,
Nilsson
B
:
Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation
.
Lancet
2002
;
360
:
2039
2045
37
Ozmen
L
,
Ekdahl
KN
,
Elgue
G
,
Larsson
R
,
Korsgren
O
,
Nilsson
B
:
Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation
.
Diabetes
2002
;
51
:
1779
1784
38
Nagata
M
,
Mullen
Y
,
Matsuo
S
,
Herrera
M
,
Clare-Salzler
M
:
Destruction of islet isografts by severe nonspecific inflammation
.
Transplant Proc
1990
;
22
:
855
856
39
Kaufman
DB
,
Platt
JL
,
Rabe
FL
,
Dunn
DL
,
Bach
FH
,
Sutherland
DE
:
Differential roles of Mac-1+ cells, and CD4+ and CD8+ T lymphocytes in primary nonfunction and classic rejection of islet allografts
.
J Exp Med
1990
;
172
:
291
302
40
Kaufman
DB
,
Gores
PF
,
Field
MJ
,
Farney
AC
,
Gruber
SA
,
Stephanian
E
,
Sutherland
DE
:
Effect of 15-deoxyspergualin on immediate function and long-term survival of transplanted islets in murine recipients of a marginal islet mass
.
Diabetes
1994
;
43
:
778
783
41
Weyrich
AS
,
Elstad
MR
,
McEver
RP
,
McIntyre
TM
,
Moore
KL
,
Morrissey
JH
,
Prescott
SM
,
Zimmerman
GA
:
Activated platelets signal chemokine synthesis by human monocytes
.
J Clin Invest
1996
;
97
:
1525
1534
42
Mandrup-Poulsen
T
,
Bendtzen
K
,
Nielsen
JH
,
Bendixen
G
,
Nerup
J
:
Cytokines cause functional and structural damage to isolated islets of Langerhans
.
Allergy
1985
;
40
:
424
429
43
Johansson
U
,
Olsson
A
,
Gabrielsson
S
,
Nilsson
B
,
Korsgren
O
:
Inflammatory mediators expressed in human islets of Langerhans: implications for islet transplantation
.
Biochem Biophys Res Commun
2003
;
308
:
474
479
44
Bottino
R
,
Balamurugan
AN
,
Tse
H
,
Thirunavukkarasu
C
,
Ge
X
,
Profozich
J
,
Milton
M
,
Ziegenfuss
A
,
Trucco
M
,
Piganelli
JD
:
Response of human islets to isolation stress and the effect of antioxidant treatment
.
Diabetes
2004
;
53
:
2559
2568
45
Grotting
JC
,
Rosai
J
,
Matas
AJ
,
Frenzel
EM
,
Payne
WD
,
Sutherland
DE
,
Najarian
JS
:
The fate of intraportally transplanted islets in diabetic rats. A morphologic and immunohistochemical study
.
Am J Pathol
1978
;
92
:
653
670
46
Bennet
W
,
Sundberg
B
,
Groth
CG
,
Brendel
MD
,
Brandhorst
D
,
Brandhorst
H
,
Bretzel
RG
,
Elgue
G
,
Larsson
R
,
Nilsson
B
,
Korsgren
O
:
Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation?
Diabetes
1999
;
48
:
1907
1914
47
Johansson
H
,
Lukinius
A
,
Moberg
L
,
Lundgren
T
,
Berne
C
,
Foss
A
,
Felldin
M
,
Kallen
R
,
Salmela
K
,
Tibell
A
,
Tufveson
G
,
Ekdahl
KN
,
Elgue
G
,
Korsgren
O
,
Nilsson
B
:
Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation
.
Diabetes
2005
;
54
:
1755
1762
48
Ruf
W
,
Edgington
TS
:
An anti-tissue factor monoclonal antibody which inhibits TF.VIIa complex is a potent anticoagulant in plasma
.
Thromb Haemost
1991
;
66
:
529
533
49
Berman
DM
,
Cabrera
O
,
Kenyon
NM
,
Miller
J
,
Tam
SH
,
Khandekar
VS
,
Picha
KM
,
Soderman
AR
,
Jordan
RE
,
Bugelski
PJ
,
Horninger
D
,
Lark
M
,
Davis
JE
,
Alejandro
R
,
Berggren
PO
,
Zimmerman
M
,
O'Neil
JJ
,
Ricordi
C
,
Kenyon
NS
:
Interference with tissue factor prolongs intrahepatic islet allograft survival in a nonhuman primate marginal mass model
.
Transplantation
2007
;
84
:
308
315
50
Koulmanda
M
,
Bhasin
M
,
Hoffman
L
,
Fan
Z
,
Qipo
A
,
Shi
H
,
Bonner-Weir
S
,
Putheti
P
,
Degauque
N
,
Libermann
TA
,
Auchincloss
H
 Jr
,
Flier
JS
,
Strom
TB
:
Curative and beta cell regenerative effects of alpha1-antitrypsin treatment in autoimmune diabetic NOD mice
.
Proc Natl Acad Sci U S A
2008
;
105
:
16242
16247
51
Louvet
C
,
Szot
GL
,
Lang
J
,
Lee
MR
,
Martinier
N
,
Bollag
G
,
Zhu
S
,
Weiss
A
,
Bluestone
JA
:
Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice
.
Proc Natl Acad Sci U S A
2008
;
105
:
18895
18900
52
Bellin
MD
,
Kandaswamy
R
,
Parkey
J
,
Zhang
HJ
,
Liu
B
,
Ihm
SH
,
Ansite
JD
,
Witson
J
,
Bansal-Pakala
P
,
Balamurugan
AN
,
Papas
K
,
Sutherland
DE
,
Moran
A
,
Hering
BJ
:
Prolonged insulin independence after islet allotransplants in recipients with type 1 diabetes
.
Am J Transplant
2008
;
8
:
2463
2470
53
Zhang
N
,
Su
D
,
Qu
S
,
Tse
T
,
Bottino
R
,
Balamurugan
AN
,
Xu
J
,
Bromberg
JS
,
Dong
HH
:
Sirolimus is associated with reduced islet engraftment and impaired β-cell function
.
Diabetes
2006
;
55
:
2429
2436
54
Cantaluppi
V
,
Biancone
L
,
Romanazzi
GM
,
Figliolini
F
,
Beltramo
S
,
Ninniri
MS
,
Galimi
F
,
Romagnoli
R
,
Franchello
A
,
Salizzoni
M
,
Perin
PC
,
Ricordi
C
,
Segoloni
GP
,
Camussi
G
:
Antiangiogenic and immunomodulatory effects of rapamycin on islet endothelium: relevance for islet transplantation
.
Am J Transplant
2006
;
6
:
2601
2611
55
Fraenkel
M
,
Ketzinel-Gilad
M
,
Ariav
Y
,
Pappo
O
,
Karaca
M
,
Castel
J
,
Berthault
MF
,
Magnan
C
,
Cerasi
E
,
Kaiser
N
,
Leibowitz
G
:
mTOR inhibition by rapamycin prevents β-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes
.
Diabetes
2008
;
57
:
945
957
56
Zahr
E
,
Molano
RD
,
Pileggi
A
,
Ichii
H
,
Jose
SS
,
Bocca
N
,
An
W
,
Gonzalez-Quintana
J
,
Fraker
C
,
Ricordi
C
,
Inverardi
L
:
Rapamycin impairs in vivo proliferation of islet beta-cells
.
Transplantation
2007
;
84
:
1576
1583
57
Nir
T
,
Melton
DA
,
Dor
Y
:
Recovery from diabetes in mice by beta cell regeneration
.
J Clin Invest
2007
;
117
:
2553
2561
58
Gao
R
,
Ustinov
J
,
Korsgren
O
,
Otonkoski
T
:
Effects of immunosuppressive drugs on in vitro neogenesis of human islets: mycophenolate mofetil inhibits the proliferation of ductal cells
.
Am J Transplant
2007
;
7
:
1021
1026
59
The Canadian-European Randomized Control Trial Group.
Cyclosporin-induced remission of IDDM after early intervention. Association of 1 yr of cyclosporin treatment with enhanced insulin secretion
.
Diabetes
1988
;
37
:
1574
1582
60
Liu
EH
,
Siegel
RM
,
Harlan
DM
,
O'Shea
JJ
:
T cell-directed therapies: lessons learned and future prospects
.
Nat Immunol
2007
;
8
:
25
30
61
Keymeulen
B
,
Vandemeulebroucke
E
,
Ziegler
AG
,
Mathieu
C
,
Kaufman
L
,
Hale
G
,
Gorus
F
,
Goldman
M
,
Walter
M
,
Candon
S
,
Schandene
L
,
Crenier
L
,
De Block
C
,
Seigneurin
JM
,
De Pauw
P
,
Pierard
D
,
Weets
I
,
Rebello
P
,
Bird
P
,
Berrie
E
,
Frewin
M
,
Waldmann
H
,
Bach
JF
,
Pipeleers
D
,
Chatenoud
L
:
Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes
.
N Engl J Med
2005
;
352
:
2598
2608
62
Herold
KC
,
Hagopian
W
,
Auger
JA
,
Poumian-Ruiz
E
,
Taylor
L
,
Donaldson
D
,
Gitelman
SE
,
Harlan
DM
,
Xu
D
,
Zivin
RA
,
Bluestone
JA
:
Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus
.
N Engl J Med
2002
;
346
:
1692
1698
63
Ludvigsson
J
,
Faresjo
M
,
Hjorth
M
,
Axelsson
S
,
Cheramy
M
,
Pihl
M
,
Vaarala
O
,
Forsander
G
,
Ivarsson
S
,
Johansson
C
,
Lindh
A
,
Nilsson
NO
,
Aman
J
,
Ortqvist
E
,
Zerhouni
P
,
Casas
R
:
GAD treatment and insulin secretion in recent-onset type 1 diabetes
.
N Engl J Med
2008
;
359
:
1909
1920
64
Bhargava
R
,
Senior
PA
,
Ackerman
TE
,
Ryan
EA
,
Paty
BW
,
Lakey
JR
,
Shapiro
AM
:
Prevalence of hepatic steatosis after islet transplantation and its relation to graft function
.
Diabetes
2004
;
53
:
1311
1317
65
Maffi
P
,
Angeli
E
,
Bertuzzi
F
,
Paties
C
,
Socci
C
,
Fedeli
C
,
De Taddeo
F
,
Nano
R
,
Di Carlo
V
,
Del Maschio
A
,
Secchi
A
:
Minimal focal steatosis of liver after islet transplantation in humans: a long-term study
.
Cell Transplant
2005
;
14
:
727
733
66
Hirshberg
B
,
Montgomery
S
,
Wysoki
MG
,
Xu
H
,
Tadaki
D
,
Lee
J
,
Hines
K
,
Gaglia
J
,
Patterson
N
,
Leconte
J
,
Hale
D
,
Chang
R
,
Kirk
AD
,
Harlan
DM
:
Pancreatic islet transplantation using the nonhuman primate (rhesus) model predicts that the portal vein is superior to the celiac artery as the islet infusion site
.
Diabetes
2002
;
51
:
2135
2140
67
al-Abdullah
IH
,
Anil Kumar
MS
,
Kelly-Sullivan
D
,
Abouna
GM
:
Site for unpurified islet transplantation is an important parameter for determination of the outcome of graft survival and function
.
Cell Transplant
1995
;
4
:
297
305
68
Gustavson
SM
,
Rajotte
RV
,
Hunkeler
D
,
Lakey
JR
,
Edgerton
DS
,
Neal
DW
,
Snead
WL
,
Penaloza
AR
,
Cherrington
AD
:
Islet auto-transplantation into an omental or splenic site results in a normal beta cell but abnormal alpha cell response to mild non-insulin-induced hypoglycemia
.
Am J Transplant
2005
;
5
:
2368
2377
69
Ao
Z
,
Matayoshi
K
,
Lakey
JR
,
Rajotte
RV
,
Warnock
GL
:
Survival and function of purified islets in the omental pouch site of outbred dogs
.
Transplantation
1993
;
56
:
524
529
70
Berman
DM
,
O'Neil
JJ
,
Coffey
LC
,
Chaffanjon
PC
,
Kenyon
NM
,
Ruiz
P
 Jr
,
Pileggi
A
,
Ricordi
C
,
Kenyon
NS
:
Long-term survival of nonhuman primate islets implanted in an omental pouch on a biodegradable scaffold
.
Am J Transplant
2009
;
9
:
91
104
71
Stagner
JI
,
Rilo
HL
,
White
KK
:
The pancreas as an islet transplantation site. Confirmation in a syngeneic rodent and canine autotransplant model
.
JOP
2007
;
8
:
628
636
72
Rafael
E
,
Tibell
A
,
Ryden
M
,
Lundgren
T
,
Savendahl
L
,
Borgstrom
B
,
Arnelo
U
,
Isaksson
B
,
Nilsson
B
,
Korsgren
O
,
Permert
J
:
Intramuscular autotransplantation of pancreatic islets in a 7-year-old child: a 2-year follow-up
.
Am J Transplant
2008
;
8
:
458
462
73
Echeverri
G
,
Starzl
T
,
McGrath
K
, et al
:
Endoscopic Gastric Submucosal Transplantation of Islets (ENDO-STI): technique and initial results in diabetic pigs
.
Am J Transplant
.
In press
.
74
Zhao
M
,
Muiesan
P
,
Amiel
SA
,
Srinivasan
P
,
Asare-Anane
H
,
Fairbanks
L
,
Persaud
S
,
Jones
P
,
Jones
J
,
Ashraf
S
,
Littlejohn
W
,
Rela
M
,
Heaton
N
,
Huang
GC
:
Human islets derived from donors after cardiac death are fully biofunctional
.
Am J Transplant
2007
;
7
:
2318
2325
75
Matsumoto
S
,
Okitsu
T
,
Iwanaga
Y
,
Noguchi
H
,
Nagata
H
,
Yonekawa
Y
,
Liu
X
,
Kamiya
H
,
Ueda
M
,
Hatanaka
N
,
Kobayashi
N
,
Yamada
Y
,
Miyakawa
S
,
Seino
Y
,
Shapiro
AM
,
Tanaka
K
:
Follow-up study of the first successful living donor islet transplantation
.
Transplantation
2006
;
82
:
1629
1633
76
Menge
BA
,
Tannapfel
A
,
Belyaev
O
,
Drescher
R
,
Muller
C
,
Uhl
W
,
Schmidt
WE
,
Meier
JJ
:
Partial pancreatectomy in adult humans does not provoke β-cell regeneration
.
Diabetes
2008
;
57
:
142
149
77
Cardona
K
,
Korbutt
GS
,
Milas
Z
,
Lyon
J
,
Cano
J
,
Jiang
W
,
Bello-Laborn
H
,
Hacquoil
B
,
Strobert
E
,
Gangappa
S
,
Weber
CJ
,
Pearson
TC
,
Rajotte
RV
,
Larsen
CP
:
Long-term survival of neonatal porcine islets in nonhuman primates by targeting costimulation pathways
.
Nat Med
2006
;
12
:
304
306
78
Hering
BJ
,
Wijkstrom
M
,
Graham
ML
,
Hardstedt
M
,
Aasheim
TC
,
Jie
T
,
Ansite
JD
,
Nakano
M
,
Cheng
J
,
Li
W
,
Moran
K
,
Christians
U
,
Finnegan
C
,
Mills
CD
,
Sutherland
DE
,
Bansal-Pakala
P
,
Murtaugh
MP
,
Kirchhof
N
,
Schuurman
HJ
:
Prolonged diabetes reversal after intraportal xenotransplantation of wild-type porcine islets in immunosuppressed nonhuman primates
.
Nat Med
2006
;
12
:
301
303
79
Kuwaki
K
,
Tseng
YL
,
Dor
FJ
,
Shimizu
A
,
Houser
SL
,
Sanderson
TM
,
Lancos
CJ
,
Prabharasuth
DD
,
Cheng
J
,
Moran
K
,
Hisashi
Y
,
Mueller
N
,
Yamada
K
,
Greenstein
JL
,
Hawley
RJ
,
Patience
C
,
Awwad
M
,
Fishman
JA
,
Robson
SC
,
Schuurman
HJ
,
Sachs
DH
,
Cooper
DK
:
Heart transplantation in baboons using alpha1,3-galactosyltransferase gene-knockout pigs as donors: initial experience
.
Nat Med
2005
;
11
:
29
31
80
Phelps
CJ
,
Koike
C
,
Vaught
TD
,
Boone
J
,
Wells
KD
,
Chen
SH
,
Ball
S
,
Specht
SM
,
Polejaeva
IA
,
Monahan
JA
,
Jobst
PM
,
Sharma
SB
,
Lamborn
AE
,
Garst
AS
,
Moore
M
,
Demetris
AJ
,
Rudert
WA
,
Bottino
R
,
Bertera
S
,
Trucco
M
,
Starzl
TE
,
Dai
Y
,
Ayares
DL
:
Production of alpha 1,3-galactosyltransferase-deficient pigs
.
Science
2003
;
299
:
411
414
81
D'Amour
KA
,
Bang
AG
,
Eliazer
S
,
Kelly
OG
,
Agulnick
AD
,
Smart
NG
,
Moorman
MA
,
Kroon
E
,
Carpenter
MK
,
Baetge
EE
:
Production of pancreatic hormone-expressing endocrine cells from human embryonic stem cells
.
Nat Biotechnol
2006
;
24
:
1392
1401
82
Kroon
E
,
Martinson
LA
,
Kadoya
K
,
Bang
AG
,
Kelly
OG
,
Eliazer
S
,
Young
H
,
Richardson
M
,
Smart
NG
,
Cunningham
J
,
Agulnick
AD
,
D'Amour
KA
,
Carpenter
MK
,
Baetge
EE
:
Pancreatic endoderm derived from human embryonic stem cells generates glucose-responsive insulin-secreting cells in vivo
.
Nat Biotechnol
2008
;
26
:
443
452
83
Byrne
JA
,
Pedersen
DA
,
Clepper
LL
,
Nelson
M
,
Sanger
WG
,
Gokhale
S
,
Wolf
DP
,
Mitalipov
SM
:
Producing primate embryonic stem cells by somatic cell nuclear transfer
.
Nature
2007
;
450
:
497
502
84
Aoi
T
,
Yae
K
,
Nakagawa
M
,
Ichisaka
T
,
Okita
K
,
Takahashi
K
,
Chiba
T
,
Yamanaka
S
:
Generation of pluripotent stem cells from adult mouse liver and stomach cells
.
Science
2008
;
321
:
699
702
85
Yu
J
,
Hu
K
,
Smuga-Otto
K
,
Tian
S
,
Stewart
R
,
Slukvin
 II
,
Thomson
JA
:
Human induced pluripotent stem cells free of vector and transgene sequences
.
Science
2009
;
324
:
797
801
86
Pinkse
GG
,
Tysma
OH
,
Bergen
CA
,
Kester
MG
,
Ossendorp
F
,
van Veelen
PA
,
Keymeulen
B
,
Pipeleers
D
,
Drijfhout
JW
,
Roep
BO
:
Autoreactive CD8 T cells associated with beta cell destruction in type 1 diabetes
.
Proc Natl Acad Sci U S A
2005
;
102
:
18425
18430
87
Zhou
Q
,
Brown
J
,
Kanarek
A
,
Rajagopal
J
,
Melton
DA
:
In vivo reprogramming of adult pancreatic exocrine cells to beta-cells
.
Nature
2008
;
455
:
627
632
88
Wilson
JM
:
Medicine. A history lesson for stem cells
.
Science
2009
;
324
:
727
728
89
Khan
M
,
Harlan
DM
:
Transplant-based treatments for the patient with long-standing type 1 diabetes
. In
Diabetes: Translating Research into Practice
.
Greenbaum
CJ
,
Harrison
LC
: Eds.
New York
,
Informa Healthcare USA
,
2008
, p.
193
208
90
Venstrom
JM
,
McBride
MA
,
Rother
KI
,
Hirshberg
B
,
Orchard
TJ
,
Harlan
D
:
Pancreas transplantation decreases survival for patients with diabetes and preserved kidney function
.
JAMA
2003
;
290
:
2817
2823
91
Heit
JJ
,
Apelqvist
AA
,
Gu
X
,
Winslow
MM
,
Neilson
JR
,
Crabtree
GR
,
Kim
SK
:
Calcineurin/NFAT signalling regulates pancreatic beta-cell growth and function
.
Nature
2006
;
443
:
345
349
92
Bosi
E
,
Braghi
S
,
Maffi
P
,
Scirpoli
M
,
Bertuzzi
F
,
Pozza
G
,
Secchi
A
,
Bonifacio
E
:
Autoantibody response to islet transplantation in type 1 diabetes
.
Diabetes
2001
;
50
:
2464
2471
93
Roelen
DL
,
Huurman
VA
,
Hilbrands
R
,
Gillard
P
,
Duinkerken
G
,
van der Meer-Prins
PW
,
Versteeg-van der Voort Maarschalk
MF
,
Mathieu
C
,
Keymeulen
B
,
Pipeleers
DG
,
Roep
BO
,
Claas
FH
:
Relevance of cytotoxic alloreactivity under different immunosuppressive regimens in clinical islet cell transplantation
.
Clin Exp Immunol
2009
;
156
:
141
148
94
Arif
S
,
Tree
TI
,
Astill
TP
,
Tremble
JM
,
Bishop
AJ
,
Dayan
CM
,
Roep
BO
,
Peakman
M
:
Autoreactive T cell responses show proinflammatory polarization in diabetes but a regulatory phenotype in health
.
J Clin Invest
2004
;
113
:
451
463
95
Han
D
,
Leith
J
,
Alejandro
R
,
Bolton
W
,
Ricordi
C
,
Kenyon
NS
:
Peripheral blood cytotoxic lymphocyte gene transcript levels differ in patients with long-term type 1 diabetes compared to normal controls
.
Cell Transplant
2005
;
14
:
403
409
96
Huurman
VAL
,
Velthuis
JHL
,
Hilbrands
R
,
Tree
TIM
,
Gillard
P
,
Van der Meer-Prins
PMJ
,
Duinkerken
G
,
Pinkse
GGM
,
Keymeulen
B
,
Roelen
DL
,
Claas
FHJ
,
Pipeleers
DG
,
Roep
BO
:
Allograft-specific cytokine profiles associate with clinical outcome after islet cell transplantation
.
Am J Transpl
2009
;
9
:
382
388
97
Gillard
P
,
Huurman
V
,
Van der Auwera
B
,
Decallonne
B
,
Poppe
K
,
Roep
BO
,
Gorus
F
,
Mathieu
C
,
Pipeleers
D
,
Keymeulen
B
:
Graves' hyperthyroidism after stopping immune suppressive therapy in type 1 diabetic islet cell recipients with pretransplant TPO-autoantibodies
.
Diabetes Care
.
In press
98
Hilbrands
R
,
Huurman
VA
,
Gillard
P
,
Velthuis
JH
,
De Waele
M
,
Mathieu
C
,
Kaufman
L
,
Pipeleers-Marichal
M
,
Ling
Z
,
Movahedi
B
,
Jacobs-Tulleneers-Thevissen
D
,
Monbaliu
D
,
Ysebaert
D
,
Gorus
FK
,
Roep
BO
,
Pipeleers
DG
,
Keymeulen
B
:
Differences in baseline lymphocyte counts and autoreactivity are associated with differences in outcome of islet cell transplantation in type 1 diabetic patients
.
Diabetes
.
In press